1. Scrip
  2. >>Business

Sanofi And Lexicon Fall Out Over Zynquista, As French Group Exits Diabetes Pact

 
• By Sten Stovall

Lexicon labelled Sanofi’s unilateral decision to exit their alliance ‘invalid’ and said the French drugmaker was thus ‘in breach of contract’. Sanofi said its move was triggered by Phase III trial data studying the dual SGLT1 and SGLT2 inhibitor in type-2 diabetes. 

Swift exit
Sanofi ‘walks’ from R&D Pact investigating Lexicon’s Zynquista in diabetes • Source: Shutterstock

An acrimonious end seems to have come to the alliance between Sanofi and Lexicon Pharmaceuticals Inc. for the development of the dual SGLT1 and SGLT2 inhibitor Zynquista (sotagliflozin) in diabetes, with the French drug maker walking away from the program after seeing results of late-stage studies of the drug and the US-based pharma calling the move ”invalid" and “in breach of contract.”

Sanofi on 26 July said it was ending the partnership, established in November 2015, after seeing results of three late-stage...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By Mandy Jackson

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 
• By Alaric DeArment

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 
• By Joseph Haas, Manas Mishra, and Sushmita Panda

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.